Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds HC Wainwright & Co. Downgrades Neovasc to Neutral

HC Wainwright & Co. Downgrades Neovasc to Neutral

HC Wainwright & Co. analyst Vernon Bernardino downgrades Neovasc (NASDAQ:NVCN) from Buy to Neutral.

byBenzinga Newsdesk

January 18, 2023

1 minute read

HC Wainwright & Co. analyst Vernon Bernardino downgrades Neovasc (NASDAQ:NVCN) from Buy to Neutral.

Barclays Maintains Overweight on Similarweb, Lowers Price Target to $8

By Benzinga Newsdesk

November 17, 8:48 AM

Barclays analyst Raimo Lenschow maintains Similarweb (NYSE:SMWB) with a Overweight and lowers the price target from $14 to $8.

SMWB

BMO’s Q4 Revenue And Profit Drop, Increases Dividend By 3%

By Akanksha Bakshi

December 1, 11:38 AM

Bank of Montreal (NYSE: BMO) reported a

BMO

SI-BONE Poised For A Surge: Analyst Highlights Upside Potential With New Product Launches

By Nabaparna Bhattacharya

July 12, 1:18 PM

Needham analyst David Saxon reiterated a Buy rating on SI-BONE, Inc (NASDAQ: SIBN),

SIBN

Cardiff Oncology Presents Novel Preclinical Data At AACR Annual Meeting 2024; Supports First-Line RAS-Mutated mCRC Clinical Study

By Benzinga Newsdesk

April 8, 4:06 PM

– In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and

CRDF

HC Wainwright & Co. Downgrades Neovasc to Neutral

Related Posts

Barclays Maintains Overweight on Similarweb, Lowers Price Target to $8

BMO’s Q4 Revenue And Profit Drop, Increases Dividend By 3%

SI-BONE Poised For A Surge: Analyst Highlights Upside Potential With New Product Launches

Cardiff Oncology Presents Novel Preclinical Data At AACR Annual Meeting 2024; Supports First-Line RAS-Mutated mCRC Clinical Study